Cagrilintide
CAGRILong-acting amylin analog.
Also known as: AM833
Overview
Cagrilintide is a long-acting amylin analog studied in appetite-regulation and weight-management research, often referenced alongside GLP-1 compounds.
A long-acting amylin analog studied for satiety and weight management through a non-incretin pathway, making it complementary to GLP-1 agonists. The CagriSema combination (with semaglutide) is a prominent research focus reporting additive weight effects.
Activates amylin and calcitonin receptors to modulate satiety and slow gastric emptying, complementary to incretin pathways.
Molecular information
AM833 — a fatty-acylated, stabilized amylin analog for once-weekly kinetics.
Pharmacokinetics
Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.
Research applications
- Amylin-pathway research
- Appetite-regulation studies
- Combination-metabolic investigations
Research protocols
Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.
Observed effects timeline
Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.
Week 1–4
Onset of satiety signaling; mild GI adaptation during titration reported.
Week 12–20
Progressive weight change reported, additive when co-studied with semaglutide.
Week 20+
Approach to maximal observed effect in study cohorts.
Research compatibility
Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.
Semaglutide
Co-studied as CagriSema under controlled designs.
GLP-1
Amylin + incretin combinations use staggered timing.
Eloralintide
Redundant amylin-receptor activity.
Insulin
Additive effects on glucose handling observed.
How to reconstitute
Use bacteriostatic water only; refrigerate reconstituted solution and use within ~28 days (often 1–3 months if it stays clear).
- 1Allow the vial to reach room temperature (15–20 minutes).
- 2Swab the stopper with alcohol and let it air dry.
- 3Add bacteriostatic water slowly down the vial wall.
- 4Swirl gently — do not shake — until clear and colorless.
- 5Refrigerate at 2–8 °C and protect from light.
Quality indicators
Uniform white powder
Lyophilized cake should be white to off-white without discoloration.
Clear solution
Reconstitutes to a clear, colorless, particle-free solution.
Cold-chain integrity
Reconstituted solution requires 2–8 °C storage.
Slight clumping
Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.
Collapsed or melted appearance
Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.
Cloudy after reconstitution
Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.
Reported observations & safety
Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.
- Gastrointestinal effects are the most commonly reported and are dose-dependent.
- Generally reported as well tolerated alongside GLP-1 agonists in research designs.
References & further reading
Cagrilintide with semaglutide (CagriSema) Phase 2 (Lancet, 2021)
Research reporting additive weight reduction when the long-acting amylin analog is combined with semaglutide.
View studyTopics
This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.
Substantial peer-reviewed research across multiple models.
This compound is part of our educational reference and is not currently stocked. Browse the catalogue for available research-grade peptides.
Browse catalogue